Niagen Bioscience Expands Its NAD+ Precursor Intellectual Property Portfolio
Los Angeles, CA – Niagen Bioscience, Inc. (NASDAQ: NAGE), a leading company in the field of NAD+ (nicotinamide adenine dinucleotide) and healthy aging, recently made an exciting announcement regarding the expansion of its NAD+ precursor intellectual property (IP) portfolio. The company obtained a new U.S. Patent, numbered 12,252,506.
The Newly Granted Patent
This patent covers the composition of matter for nicotinamide riboside (NR) salt forms, including NR Malate and NR Tartrate, and other NR derivatives. NR is a form of vitamin B3 and functions as an NAD+ precursor, meaning it plays a crucial role in the production of NAD+ within the body.
Implications for Niagen Bioscience
The granting of this patent is a significant achievement for Niagen Bioscience, as it strengthens their position in the competitive market of NAD+ precursors. This patent will enable the company to protect its intellectual property and potentially increase its revenue through licensing and partnership opportunities.
Benefits for Consumers
For consumers, this patent may lead to more options for NAD+ precursor supplements, as Niagen Bioscience can now explore the production and marketing of various NR salt forms and derivatives. The increased competition in the market could potentially lead to more affordable prices and better availability of these supplements.
Global Impact
The advancements in NAD+ precursor research and technology have the potential to significantly impact the world, especially in the areas of aging and disease prevention. As more companies enter the market and develop new, effective supplements, the demand for NAD+ precursors is expected to grow. This could lead to increased investments in research and development, as well as the creation of new jobs in the industry.
Conclusion
In summary, Niagen Bioscience’s recent acquisition of a patent for NR salt forms and derivatives is a significant milestone in the NAD+ precursor market. This patent will not only benefit Niagen Bioscience but could also lead to more options for consumers and contribute to the global advancement of NAD+ precursor research and technology. As the world continues to age and populations grow, the demand for NAD+ precursors is expected to increase, making this an exciting time for the industry.
- Niagen Bioscience expands NAD+ precursor intellectual property portfolio
- New patent covers composition of matter for nicotinamide riboside (NR) salt forms and derivatives
- Company strengthens position in competitive market
- Potential for increased revenue through licensing and partnership opportunities
- More options for consumers, potentially leading to more affordable prices and better availability
- Significant impact on aging and disease prevention research and industry development
